MedTrace Logo

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

NCT03873870 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1916

Last updated 2024-01-17

No results posted yet for this study

Summary

This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga -DOTATATE PET scans

PET scan using 68Ga-DOTATATE contrast

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Ur Metser, M.D. · Princess Margaret Cancer Centre

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-28
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03873870 on ClinicalTrials.gov